CD4 and neoplasm: Single-cell RNA sequencing (scRNA-seq) revealed that OV-mOX40L treatment activated tumor-infiltrating CD4 and CD8 T cells and decreased Tregs, along with the reprogramming of macrophages and neutrophils to a more pro-inflammatory anti-tumor state.